Seattle Genetics Inc
What’s Nektar Therapeutics’ Guidance for Fiscal 2018?
For full fiscal 2018, the company expects to register R&D (research and development) expenses of $400 million to $425 million.
What Does the Future Hold for Seattle Genetics?
Seattle Genetics has surpassed all estimates for earnings per share in the past.
Ultragenyx Woos Investors with Good Returns in Mid-Cap Space
Ultragenyx Pharmaceutical (RARE) rebounded on December 14, 2015, after falling for four consecutive days. The stock rose 3.8% and was the top performer among the mid-cap stocks that day.
Horizon Rose and Outperformed IBB’s Mid-Cap Stocks
Horizon Pharma rose 5.4% on November 16, 2015. The stock rose due to the update at the shareholder meeting regarding the Depomed acquisition.
Seattle Genetics’ 1Q16 Earnings: What Are Analysts Expecting?
Seattle Genetics is set to release its first-quarter 2016 earnings on April 28, 2016. Analysts estimate revenues of around $116 million for 1Q16.
XBI Moving Averages Are on the Rise
For the week ended September 11, 2015, the SPDR S&P Biotechnology ETF (XBI) saw a big jump in the number of stocks trading above the 20-day moving average.
Seattle Genetics Leads XBI Mid-Cap Stocks
Seattle Genetics (SGEN) rose 14.56% for the week ended September 11, 2015. The stock closed at $45.01 and moved back to 20-day, 50-day, and 100-day moving averages.
XBI’s Mid Caps: Ionis Gives Update on Nusinersen Phase 2 Study
The mid-cap stocks of the SPDR S&P Biotech ETF (XBI) rose 1% on April 20, 2016. Within XBI, Ionis Pharmaceuticals’ stock closed at $43.62 on the day.
Seattle Genetics Posted Strong Q2 2018 Results, Stock Rose
Seattle Genetics reported sales of $170.2 million in the second quarter, which represented 57.2% growth YoY (year-over-year).
Seattle Genetics and Bristol-Myers Initiate ADCETRIS Trial
On December 23, 2015, Seattle Genetics and Bristol-Myers Squibb announced the initiation of Phase 1 and 2 clinical trials of ADCETRIS.
Wall Street Is Bullish on Nektar Stock despite Stock Price Slump
Nektar is a development-stage biotechnology company that has a drug pipeline focused on the treatment of cancer, autoimmune diseases, and chronic pain.
What’s behind Nektar Therapeutics’ ~38% Fall in June?
On June 27, Nektar Therapeutics (NKTR) ended the trading day at a closing price of $46.25.
How’s Alkermes Positioned Financially in September?
In the second quarter, Alkermes (ALKS) reported revenues of $304.6 million—compared to $218.8 million in the second quarter of 2017.
Analyzing Seattle Genetics’ Key Collaborations
Seattle Genetics (SGEN) is focused on maximizing Adcetris’ market reach. Currently, the product is sold in 71 countries.
What Seattle Genetics’ Bottom-Line Trend Indicates
In December 2018, of the total 13 analysts covering Seattle Genetics, eight analysts have given Seattle Genetics stock a “buy” or higher rating.
How’s Seattle Genetics Positioned?
Seattle Genetics generated total revenues of $169.42 million in the third quarter of 2018 as compared with $135.29 million in the comparable period of 2017.
A Financial Overview of Ionis Pharmaceuticals in October
Ionis Pharmaceuticals generated Q2 2018 revenues of $118.0 million compared to $122.3 million in Q2 2017, which reflected ~15.0% YoY growth.
Cara Therapeutics: Performance and Estimates for Q3
Cara Therapeutics reported revenues of $2.87 million in the second quarter compared to no revenues in the second quarter of 2017.
Seattle Genetics: Impact of the Cascadian Acquisition
Seattle Genetics acquired clinical-stage biopharmaceutical company Cascadian in March for $614.1 million at $10.0 per share.
Exploring Seattle Genetics’ Operational Performance
Seattle Genetics (SGEN) incurred a cost of sales of $13.16 million in the second quarter—compared to $8.06 million in the second quarter of 2017.
What’s Driving Seattle Genetics Stock in 2018?
Seattle Genetics generated total revenues of $170.17 million in the second quarter—compared to $108.22 million in the same period in 2017.
Ionis Pharmaceuticals’ Revenue Stream
Ionis’s Commercial Revenues segment reported second-quarter revenues of $57.0 million, compared to $24.0 million during the second quarter of 2017.
A Look at Sage Therapeutics’ NMDA Receptor Portfolio
Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders.
Estimates and Recommendations for Shire on September 19
Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017.
Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy
Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating investigational Lenti-D gene therapy.
What Do Analysts Expect from Ionis’s Q2 2018 Earnings?
Ionis is expected to report 30.0% growth in revenues to $135.5 million in the second quarter of 2018 as compared to $104.2 million in Q2 2017.
Bluebird Bio Misses Analysts’ Estimates in Q2 2018
Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates.
Incyte’s Q2 2018 Earnings Beat Analysts’ Revenue Estimates
Incyte (INCY) beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.27 on revenues of $521.5 million in Q2 2018.
Seattle Genetics Increased Its Fiscal 2018 Outlook
During the second-quarter earnings release, Seattle Genetics provided an increased guidance range for its fiscal collaboration sales.
Why Advaxis Stock Is Soaring Today
Today, Advaxis (ADXS) is trading at $1.43, which represents a rise of ~16.80% from yesterday’s close of $1.22.
How Analysts Are Rating Puma Biotechnology in July
On July 5, Puma Biotechnology (PBYI) stock closed at $58.75, which represents a 25% growth from its 52-week low of $47 on June 7.
Merck’s Keytruda Receives a New Approval
In June, the FDA approved Merck & Company’s Keytruda for the treatment of individuals with refractory primary mediastinal large B-cell lymphoma.
TapImmune Stock: Why It Spiked 84% Last Week
TapImmune (TPIV) stock saw an ~84.1% hike during the week of June 1–8. On June 8, it closed at $9.
CRISPR Stock Has Seen Soild Growth in the Last 12 Months
CRISPR Therapeutics has risen 24% between May 11 and May 17.
Key Updates on Akcea Therapeutics’ Volanesorsen
Ionis Pharmaceuticals’ (IONS) Volanesorsen is a drug for the treatment of familial chylomicronemia syndrome (or FCS) and familial partial lipodystrophy (or FPL).
A Look at Ionis’s Key Revenue Drivers in 4Q17
Ionis Pharmaceuticals (IONS) reported 7.5% growth in revenues to $172.3 million during 4Q17 as compared to revenues of $160.3 million during 4Q16.
Key Updates on Novartis’s Kymriah
In December 2017, Novartis (NVS) presented updated results from the Juliet clinical trial, which demonstrated sustained responses of Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (or DLBCL).
How Is Novartis’s Kymriah Positioned for 2018?
FDA and EC approvals for label expansion are expected to further boost Kymriah’s sales growth.
Opdivo Could Be Long-Term Growth Driver for Bristol-Myers Squibb
In 1Q17, 2Q17, and 3Q17, Opdivo reported revenues of $1.1 billion, $1.2 billion, and $1.3 billion, respectively.
What Analysts Recommend for United Therapeutics in November 2017
In November 2017, the U.S. Food and Drug Administration (or FDA) granted United Therapeutics’ (UTHR) Adcirca Pediatric exclusivity until May 21, 2018.
What Analysts Recommend for United Therapeutics in August 2017
In April 2017, United Therapeutics (UTHR) and 3D Systems (DDD) declared their plans to develop solid organ scaffolds for human transplants.
What Analysts Recommend for United Therapeutics in June 2017
Thirteen analysts covered United Therapeutics in June 2017. Two analysts recommended a “strong buy.”
Adcetris-Opdivo Combination for Classical Hodgkin Lymphoma
Bristol-Myers Squibb and Seattle Genetics are evaluating the Adcetris-Opdivo combination to treat patients with relapsed classical Hodgkin Lymphoma.
Updates on the Adcetris and Opdivo Combination
Bristol-Myers Squibb and Seattle Genetics are evaluating a combination of Opdivo with Adcetris to treat refractory or relapsed classical Hodgkin Lymphoma.
Data from the Checkmate-205 Study Evaluating Opdivo
Follow-up data were released from the Checkmate-205 study. It evaluated long-term effects of PD-1 inhibitors in patients with classical Hodgkin Lymphoma.
How Is Mylan’s Generics Segment Doing?
Mylan’s (MYL) 3Q16 revenues were mainly driven by a 17.0% rise in sales for its Generics segment. The segment reported $2.6 billion in sales in 3Q16.
IBB Holdings: How Are Their Moving Averages Trending?
The iShares Nasdaq Biotechnology ETF (IBB) has 189 stocks in its portfolio. As of June 6, 2016, 87% of IBB’s stocks were trading above their 20-day moving averages.
Ionis’s Metabolic Segment: Phase I and Phase II Studies
Ionis Pharmaceuticals (IONS) is developing drugs for the treatment of various types of metabolic disorders, including diabetes, obesity, and non-alcoholic steatohepatitis.
Seattle Genetics’ Valuation: How Does It Compare?
We believe that the enterprise-value-to-revenue multiple is the best measure for valuing Seattle Genetics (SGEN) and similar companies.
What Can We Expect from Seattle Genetics’s Adcetris in 1Q16?
Adcetris is an anti-CD30 monoclonal antibody that targets CD30, which is a marker for lymphoma.
What’s Ionis Pharmaceuticals Doing with IONIS-TTR?
In March 2010, Ionis entered into a preferred partner alliance with GlaxoSmithKline (GSK) for the development and commercialization of IONIS-TTR.
Existing Chemotherapy Drugs for Lymphoma
Opdivo is under phase II study for the use in the treatment of relapsed or refractory classical Hodgkin’s lymphoma.
EMA Validates Opdivo’s Application for Additional Indications
Opdivo is an oncology drug from Bristol-Myers Squibb that is already approved by the FDA and EMA for the treatment of patients with melanoma. On March 30, EMA validated the type-II variation application for extending the current indications for Opdivo.
XBI on a Downward Slope, but How Steep?
On March 16, pressure on biotech and healthcare continued, with the SPDR S&P Biotech ETF (XBI) losing another 1.2% that day and closing at $48.31.
Pomalyst and Abraxane Revenues Are Critical for Celgene
Pomalyst and Abraxane are the next largest revenue generators for Celgene (CELG) after Revlimid. Their revenue growth is critical for Celgene to achieve revenues of $20 billion by 2020.
ALNY and JAZZ Hindered the Top 10 Mid-Cap Stocks on October 21
The top ten mid-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) outperformed the IBB and the SPDR S&P 500 ETF (SPY) as of October 21, with a return of -0.2% compared to IBB’s -0.5% and SPY’s -0.6%.
Medivation and Bluebird Led IBB’s Mid-Cap Stocks Last Week
Medivation and Bluebird led IBB’s mid-cap stocks for the week ended September 18, 2015.
Valuation Multiples for Biotechnology ETFs in Week Ended July 24
Within the iShares Nasdaq Biotechnology ETF (IBB), the biotechnology sector has a P/B ratio of 11.54x. The P/B ratio for the pharmaceuticals sector is 11.32x.